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CASE REPORT
Clozapine induced pancytopenia 
leading to severe sepsis: an unusual early 
complication
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and Jegarajah Indrakumar2
ABSTRACT 
Background: Clozapine is a second generation antipsychotic used to treat resistant schizophrenia and other psy-
chotic illnesses. Leucopenia or agranulocytosis is a rare side effect of this drug. Pancytopenia is an extremely rare side 
effect of clozapine and literature review showed only one such case in where the pancytopenia developed several 
months after starting clozapine together with other antipsychotic drugs.
Case presentation: A 26-year-old Sri Lankan male was admitted with fever for 3 days. Apart from generalized body 
aches there were no other significant symptoms. His blood counts showed pancytopenia. He was being treated for 
a resistant schizophrenia and clozapine was started only 4 weeks before. Common causes for pancytopenia were 
excluded, and a diagnosis of clozapine induced pancytopenia was made. He was managed in the intensive care unit 
with broad spectrum antibiotics, antifungals and granulocyte colony stimulating factors. He made a complete recov-
ery after 4 weeks.
Conclusion: This is a rare and probably the first reported case of early onset clozapine induced pancytopenia com-
plicated by severe sepsis recovering completely.
Keywords: Clozapine, Pancytopenia
© 2015 Pushpakumara et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Clozapine is an atypical antipsychotic drug. It relieves 
both negative and positive symptoms of schizophrenia 
and is the drug of choice in resistant schizophrenia [1, 2]. 
Clozapine causes leucopenia or agranulocytosis as a rare 
side effect. Clozapine induced pancytopenia is even rarer 
than leucopenia and review of literature showed only one 
published case. Agranulocytosis is defined as granulocyte 
count of <0.5 × 103/µl, and leukopenia is defined as white 
blood cell (WBC) count of <3.5 × 103/µl. The causes for 
the blood dyscrasias are believed to be due to idiosyn-
cratic (type B) reactions, immune-mediated or toxic sup-
pression of hemopoietic precursors due to prolonged 
administration [2]. In our patient early occurrence of 
pancytopenia is most likely due to an idiosyncratic drug 
reaction.
Case presentation
A 26-year-old Sri Lankan male was admitted to hospital 
with fever for 3 days and body aches. He did not have any 
other significant symptoms. He was diagnosed of having 
schizophrenia 4 years ago and was attending a psychiatric 
clinic. He was started on clozapine, 4 weeks ago (200 mg 
daily), because of inadequate control of symptoms with 
conventional antipsychotics. On examination he was febrile 
(102 °F), not pale or icteric. He did not have lymphadenop-
athy. Blood pressure was 130/80 mmHg and pulse rate was 
110  bpm with good volume. His respiratory rate was 32 
cycles per minute. Examination of the abdomen, cardiovas-
cular and respiratory systems were unremarkable.
His full blood count (FBC), which was done a day prior 
to hospital admission showed white blood cell count 
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(WBC) 2.9  ×  103/µl, absolute neutrophil count 667/µl 
(23  %), lymphocytes 2117/µl (73  %), Hemoglobin (Hb) 
11.3 g/dl, platelet 188 × 103/µl. The first FBC during the 
hospital stay showed reduced blood counts, of which 
WBC 0.2 × 103/µl with absolute neutrophil count (ANC) 
110/µl, lymphocyte count 80/µl, Hb 12.2 g/dl and platelet 
972 × 103/µl. The C reactive protein was (CRP) 270 mg/L 
(<6  mg/L). His chest X ray, ultrasound scan (USS) of 
abdomen and pelvis, urine full report was normal. Serol-
ogy for dengue virus, human immunodeficiency virus 
and parvo B19 virus were negative. Electrocardiogram 
(ECG) showed sinus tachycardia.
Clinical diagnosis of neutropenic sepsis was made. He 
was treated with intravenous imipenum, vancomycin, 
clindamycin, metronidazole and fluconazole. His serial 
blood cultures, urine cultures and sputum cultures were 
negative. His FBC was monitored twice daily throughout 
hospital stay, showed severe neutropenia and thrombo-
cytopenia which later complicated by anemia from the 
3rd day of hospital stay (Table  1; Fig.  1). The reticulo-
cyte count was 1.1  % (normal 0.5–2.5). The patient was 
transferred to intensive care unit (ICU) on the 3rd day 
and treated with granulocyte colony stimulating fac-
tors (G-CSF) 300 µg daily for 10 days. On the 5th day he 
developed swelling of his left inguinal region with mild 
skin induration. The initial USS of left groin showed only 
subcutaneous tissue oedema. This subsequently pro-
gressed to an abscess which was drained. His white cell 
count and platelet count improved with 10 days of treat-
ment with G-CSF. Hemoglobin normalized in 4 weeks of 
treatment. At this stage his WBC count was 12 ×  103/
µl with absolute neutrophil count 7200/µl (60 %), hemo-
globin 12.6  g/dl and platelets 212  ×  103/µl. He was 
started on conventional antipsychotics without clozapine 
for his psychiatric condition.
Discussion
This case illustrates an extremely rare complication of 
pancytopenia caused by clozapine. Clozapine is known to 
cause agranulocytosis or neutropenia as a rare side effect. 
Approximately 2.7  % of patients treated with clozapine 
develop neutropenia, of which 0.9 % develops agranulo-
cytosis [3]. Most cases (50–80 %) occur during 18 weeks 
after commencing the treatment [3–5].
Baseline FBC should be routinely done before com-
mencing clozapine and total WBC should be more than 
4 × 103/µl with ANC more than 2.5 × 103/µl [5, 6]. It is 
recommended that weekly FBC should be done to detect 
blood dyscrasia early. The patient’s WBC count, at the 
time of starting clozapine was 7.7  ×  103/µl with ANC 
3927/µl (51 %), lymphocytes 3080/µl (40 %), eosinophils 
462/µl (6  %), and platelets 260 ×  103/µl. Hematological 
results are reported as ‘green’ (safe to continue treat-
ment), ‘amber’ (borderline low or falling result) and ‘red’ 
(below the acceptable reference range). If the WBC sub-
sequently drops below the ‘red’ cut-off of 3 ×  103/µl or 
Table 1 Summary of the investigations during the first 18 days of hospital stay
WBC white blood cells, ANC absolute neutrophil count, Hb hemoglobin, RBC red blood cell count, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, 
MCHC mean corpuscular hemoglobin concentration, PCV pack cell volume, Plt platelet, ALT alanine transaminase, AST aspartate transaminase, Alb albumin, Prot total 
protein, S cr serum creatinine, BU blood urea, Na+ serum sodium, K+ serum potassium, CRP C reactive protein
Investigation D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18
WBC (×103/μl) 0.20 0.32 0.40 0.60 0.60 0.80 0.32 0.61 0.82 1.0 3.5 9.5 20 27.7 35.5 37.2 36.1 29.4
ANC (×103/μl) 0.11 0.10 0.16 0.09 0.12 0.14 0.14 0.28 0.15 0.34 1.8 6.9 16.5 21.6 28 29.6 31 25
Hb (g/dl) 12.2 11.1 10.7 11.5 9.6 9.5 8.9 8.4 8.7 8.1 8.8 8.7 8.3 8.4 8.5 8.2 7.1 8.4
RBC (×106/μl) 4.19 4.21 3.95 3.95 4.01 4.65 3.56 3.88 4.28 4.94 4.22 3.98 4.11 4.55 4.82 4.77 4.36 4.29
MCV (fL) 84 85 85.4 85.3 85.4 84 83.1 86 84.1 83.1 85 84.2 83.2 85 84.1 86 86.2 85.3
MCH (pg) 32.0 30.1 29.8 30 28.8 29.1 31 32.2 31.3 33 34 32.1 33.4 32 34 33.1 33 33.2
MCHC (g/dl) 34.9 35.1 34.9 35.2 33.7 34.4 35 35.2 33 34 33.2 34 33.2 35 35.2 34.8 33.8 32.7
PCV (%) 35 33 30 36 28 27 27 25 25 26 24 26 26 25 26 25 22 26
Plt (×103/μl) 97 79 53 82 75 64 70 57 89 144 196 247 254 232 212 200 201 283
ALT (IU/l) 43 42 35 63 58 60 53 48 56 62 49 38 23 30
AST (IU/l) 103 114 67 108 70 65 68 74 80 68 52 50 65 42
Alb (g/l) 22 23 28 26
Prot (g/l) 44 56 60 60
S cr (μmol/l) 56.2 71 75 64 51 47 66 73 68
BU (mmol/l) 15.7 14.9 9.3 7.0 6.7 4.3 4.3 4.6 3.8 4.2 5.0 4.8 3.8 2.5
Na+ (mmol/l) 134 132 140 147 148 154 132 153 143 140 138 132 136 145 138 136
K+ (mmol/l) 4.4 3.6 3.5 3.8 3.3 3.4 4.1 5.3 4.8 3.9 4.0 3.1 3.0 3.2 4.1 4.8
CRP (mg/l) 270 30 34
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the neutrophil count falls below 1.5 ×  103/µl, clozapine 
treatment must be stopped [6]. In this patient pancyto-
penia was detected at 4 weeks of clozapine treatment and 
there were no blood counts done during this period.
There was only one reported case of 57-year-old male 
with clozapine induced pancytopenia who was subse-
quently managed with electroconvulsive therapy (ECT) 
[7]. This patient was on clozapine for several years which 
was later combined with fluphenazine and promazine. He 
developed neutropenia after 1  year of combined antip-
sychotics therapy. Clozapine was stopped and restarted 
after 1  year and the patient had developed pancytope-
nia after about one and half year of therapy. His blood 
counts had spontaneously improved within 7 weeks after 
stopping clozapine. However In our patient the pancyto-
penia occurred within the first 4 weeks of treatment initi-
ated with with clozapine.
Stübner et  al. described the blood dyscrasias induced 
by psychotropic drugs after analyzing 122,562 patients 
in 35 psychiatric institutions since 1993–2000 [8]. In this 
study, 107 cases of hematological changes had been doc-
umented with an incidence of 0.0873  %. Of these, pan-
cytopenia was seen only in 2 and rest were neutropenia 
(63 cases), thrombocytopenia (16 cases), agranulocytosis 
(22 cases) and neutropenia thrombocytopenia (4 cases). 
Of these 2 cases of pancytopenia, both carbamazepine 
and lovastatin were rated as probable causative agents in 
combination in one case. In the other case, pancytopenia 
Fig. 1 Demonstration of pancytopenia and its recovery with the treatment
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was observed during treatment with trimipramine. Clo-
zapine induced pancytopenia was not observed in this 
study.
Recovery of blood dyscrasia usually occurs up to 
4  weeks after clozapine withdrawal, but there were 
exceptions—in one case report thrombocytopenia and 
leucopenia both occurred during clozapine treatment 
and persisted for 13  weeks [7]. Our patient recovered 
successfully from clozapine induced pancytopenia within 
3 weeks. We emphasize that every patient who is started 
on clozapine need very close monitoring of FBC to detect 
blood dyscrasia to minimize serious complications.
Conclusion
Clozapine induced pancytopenia is extremely rare and 
periodic FBC should be done to detect blood dyscrasia 
early. We report an unusual and early complication of 
clozapine induced pancytopenia leading to severe sepsis 
recovered with antibiotics, granulocyte colony stimulat-
ing factors and supportive care.
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